Technical Analysis for OCUP - Ocuphire Pharma, Inc.

Grade Last Price % Change Price Change
B 7.12 2.30% 0.16
OCUP closed up 2.3 percent on Friday, January 15, 2021, on 75 percent of normal volume.

Trend Table & Recent EOD Signals

ADX Long Term Intermediate Term Short Term
Strong Up Up Up
Historical OCUP trend table...

Date Alert Name Type % Chg
Doji - Bearish? Reversal 0.00%
Wide Bands Range Expansion 0.00%
Wide Bands Range Expansion 2.30%
MACD Bearish Signal Line Cross Bearish 8.04%
20 DMA Support Bullish 8.04%
1,2,3 Pullback Bullish Bullish Swing Setup 8.04%
Non-ADX 1,2,3,4 Bullish Bullish Swing Setup 8.04%
NR7 Range Contraction 8.04%
Wide Bands Range Expansion 8.04%
Down 3 Days in a Row Weakness 8.04%
Older End-of-Day Signals for OCUP ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
10 DMA Support 2 days ago
Rose Above 10 DMA 2 days ago
60 Minute Opening Range Breakdown 2 days ago
Down 3% 2 days ago
Down 2 % 2 days ago
View Earlier Intraday Alerts

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.


Ocuphire Pharma, Inc. Description

Ocuphire is a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing therapies for the treatment of several eye disorders. Ocuphire’s pipeline currently includes two small-molecule product candidates targeting front and back of the eye indications. The company’s lead product candidate, Nyxol® Eye Drops, is a once-daily preservative-free eye drop formulation of phentolamine mesylate, a non-selective alpha-1 and alpha-2 adrenergic antagonist designed to reduce pupil size, and is being developed for several indications, including dim light or night vision disturbances, pharmacologically-induced mydriasis, and presbyopia. Ocuphire’s second product candidate, APX3330, is a twice-a-day oral tablet, designed to inhibit angiogenesis and inflammation pathways relevant to retinal and choroidal vascular diseases, such as diabetic retinopathy and diabetic macular edema. As part of its strategy, Ocuphire will continue to explore opportunities to acquire additional ophthalmic assets and to seek strategic partners for late stage development, regulatory preparation, and commercialization of drugs in key global markets.


Sector: Healthcare
Industry: Biotechnology
Keywords: Eye Organ Systems Diabetes Inflammation Ophthalmic Ophthalmology Vascular Diseases Retina Diabetic Retinopathy Macular Edema Blindness Vision Diabetic Macular Edema Retinopathy Night Vision Molecule Product Angiogenesis Presbyopia

Is OCUP a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength


Indicator Value
52 Week High 7.65
52 Week Low 1.2626
Average Volume 72,619
200-Day Moving Average 3.21
50-Day Moving Average 5.84
20-Day Moving Average 6.49
10-Day Moving Average 7.06
Average True Range 0.56
ADX 33.43
+DI 24.33
-DI 14.59
Chandelier Exit (Long, 3 ATRs ) 5.97
Chandelier Exit (Short, 3 ATRs ) 6.96
Upper Bollinger Band 7.78
Lower Bollinger Band 5.21
Percent B (%b) 0.74
BandWidth 39.60
MACD Line 0.35
MACD Signal Line 0.38
MACD Histogram -0.0238
Fundamentals Value
Market Cap 77.19 Million
Num Shares 10.8 Million
Price-to-Sales 0.00
Price-to-Book 0.00
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 8.01
Resistance 3 (R3) 7.94 7.57 7.86
Resistance 2 (R2) 7.57 7.35 7.61 7.81
Resistance 1 (R1) 7.35 7.21 7.17 7.42 7.76
Pivot Point 6.98 6.98 6.89 7.02 6.98
Support 1 (S1) 6.76 6.76 6.58 6.83 6.48
Support 2 (S2) 6.39 6.62 6.43 6.43
Support 3 (S3) 6.17 6.39 6.38
Support 4 (S4) 6.24